PDE4A and psoriatic arthritis: PDE4-selective inhibitors have now been approved for the oral treatment of chronic obstructive pulmonary disease [6], psoriatic arthritis and plaque psoriasis [7], and as a topical treatment for atopic dermatitis [8]; they are also being considered as therapeutics for diseases of the CNS [9,10].